ID: ALA3936499

Max Phase: Preclinical

Molecular Formula: C18H19NO3

Molecular Weight: 297.35

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCOC(=O)c1cc(Cc2ccccc2)c(=O)n2c1CCC2

Standard InChI:  InChI=1S/C18H19NO3/c1-2-22-18(21)15-12-14(11-13-7-4-3-5-8-13)17(20)19-10-6-9-16(15)19/h3-5,7-8,12H,2,6,9-11H2,1H3

Standard InChI Key:  NYRCMXDULCKRAA-UHFFFAOYSA-N

Associated Targets(Human)

Phosphodiesterase 3 1749 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 297.35Molecular Weight (Monoisotopic): 297.1365AlogP: 2.56#Rotatable Bonds: 4
Polar Surface Area: 48.30Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 2.64CX LogD: 2.64
Aromatic Rings: 2Heavy Atoms: 22QED Weighted: 0.81Np Likeness Score: -0.42

References

1.  (2016)  Indolizinone based derivatives as potential phosphodiesterase 3 (PDE3) inhibitors and a process for the preparation thereof, 

Source

Source(1):